News | January 29, 2022
DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The product is expected to be available in a week’s time
The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19
Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis
This is Enzene Biosciences third biosimilar to be approved
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
